Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies
John N. Allan(Cornell University), Jennifer R. Brown(Dana-Farber Cancer Institute), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Richard R. Furman(Cornell University), Pietro Taverna, Gary D Acton(Cancer Research UK), Krish Patel, John M. Pagel(University of Washington), Judith A. Fox(Sunesis (United States)), Mazyar Shadman(University of Washington), Javier Pinilla Ibarz(Moffitt Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Michael Y. Choi(University of California San Diego), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), William G. Wierda(University of Maryland, Baltimore), Douglas E. Gladstone(Northwell Health), Renee Ward(Sunesis (United States)), Susan O’Brien(University of California, Irvine)
Cited by 28
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k